TipRanks
United Therapeutics (MX:UTHR)
:UTHR
Mexico Market
UTHR
United Therapeutics
RESEARCH TOOLSreports

United Therapeutics (UTHR) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

UTHR Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
11 Buy
2 Hold
1 Sell
Based on 14 analysts giving stock ratings to
United
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UTHR Stock 12 Month Forecast

Average Price Target

$12,636.22
▲(30.54% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $12,636.22 with a high forecast of $16,049.85 and a low forecast of $6,948.64. The average price target represents a 30.54% change from the last price of $9,680.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5671":"$5,671","16050":"$16,050","8265.75":"$8,265.8","10860.5":"$10,860.5","13455.25":"$13,455.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16049.8489455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12636.221409276432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6948.64048464,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5671,8265.75,10860.5,13455.25,16050],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9680,10169.988380423078,10659.976760846153,11149.965141269231,11639.953521692307,12129.941902115384,12619.930282538462,13109.91866296154,13599.907043384615,14089.895423807691,14579.883804230769,15069.872184653846,15559.860565076924,{"y":16049.8489455,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9680,9907.401646867418,10134.803293734836,10362.204940602252,10589.60658746967,10817.008234337089,11044.409881204507,11271.811528071925,11499.213174939343,11726.614821806761,11954.016468674177,12181.418115541595,12408.819762409013,{"y":12636.221409276432,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9680,9469.895421895384,9259.79084379077,9049.686265686154,8839.581687581538,8629.477109476924,8419.372531372308,8209.267953267692,7999.163375163077,7789.058797058462,7578.954218953846,7368.849640849231,7158.745062744616,{"y":6948.64048464,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5672.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8085,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8085,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8085,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8085,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8062.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9643.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9643.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9884.33,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9680,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9680,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9680,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9680,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$16,050Average Price Target$12,636Lowest Price Target$6,949
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MX:UTHR
Jessica Fye
J.P. Morgan
J.P. Morgan
$13,406.34→$13,123.11
Buy
35.57%
Upside
Assigned
10/28/26
United Therapeutics price target lowered to $695 from $710 at JPMorganUnited Therapeutics price target lowered to $695 from $710 at JPMorgan
Cantor Fitzgerald Analyst forecast on MX:UTHR
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$13,217.52→$16,049.85
Buy
65.80%
Upside
Reiterated
10/26/26
United Therapeutics price target raised to $850 from $700 at Cantor FitzgeraldUnited Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
RBC Capital Analyst forecast on MX:UTHR
Lisa Walter
RBC Capital
RBC Capital
$13,368.58→$13,160.88
Buy
35.96%
Upside
Reiterated
10/22/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
Raymond James Analyst forecast on MX:UTHR
Tiago Fauth
Raymond James
Raymond James
$12,934.29→$13,538.52
Buy
39.86%
Upside
Reiterated
10/20/26
United Therapeutics price target raised to $717 from $685 at Raymond JamesUnited Therapeutics price target raised to $717 from $685 at Raymond James
Leerink Partners Analyst forecast on MX:UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
$12,934.29→$13,689.58
Buy
41.42%
Upside
Assigned
10/20/26
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), United Therapeutics (UTHR)
Wells Fargo Analyst forecast on MX:UTHR
Benjamin Burnett
Wells Fargo
Wells Fargo
$13,217.52
Buy
36.54%
Upside
Reiterated
10/16/26
Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN), United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)
Goldman Sachs Analyst forecast on MX:UTHR
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$6,061.18→$6,948.64
Sell
-28.22%
Downside
Reiterated
10/15/26
United Therapeutics price target raised to $368 from $321 at Goldman SachsUnited Therapeutics price target raised to $368 from $321 at Goldman Sachs
UBS Analyst forecast on MX:UTHR
Ashwani Verma
UBS
UBS
$13,689.58
Buy
41.42%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), United Therapeutics (NASDAQ: UTHR) and Johnson & Johnson (NYSE: JNJ)
Bank of America Securities Analyst forecast on MX:UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$10,555.14
Hold
9.04%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)
Morgan Stanley Analyst forecast on MX:UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$10,687.31
Hold
10.41%
Upside
Reiterated
10/07/26
Morgan Stanley Releases a Hold Rating on United Therapeutics (UTHR)
BTIG Analyst forecast on MX:UTHR
Julian Harrison
BTIG
BTIG
$13,746.22
Buy
42.01%
Upside
Upgraded
10/01/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)
Jefferies Analyst forecast on MX:UTHR
Roger Song
Jefferies
Jefferies
$13,293.05
Buy
37.32%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Kazia Therapeutics (NASDAQ: KZIA) and FocalTherics (NASDAQ: FOCL)
TD Cowen Analyst forecast on MX:UTHR
Joseph Thome
TD Cowen
TD Cowen
$12,745.47
Buy
31.67%
Upside
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Medtronic (NYSE: MDT)
H.C. Wainwright Analyst forecast on MX:UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$12,462.24
Buy
28.74%
Upside
Reiterated
08/06/26
Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained
Argus Research Analyst forecast on MX:UTHR
Jasper Hellweg
Argus Research
Argus Research
$10,574.02
Buy
9.24%
Upside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MX:UTHR
Jessica Fye
J.P. Morgan
J.P. Morgan
$13,406.34→$13,123.11
Buy
35.57%
Upside
Assigned
10/28/26
United Therapeutics price target lowered to $695 from $710 at JPMorganUnited Therapeutics price target lowered to $695 from $710 at JPMorgan
Cantor Fitzgerald Analyst forecast on MX:UTHR
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$13,217.52→$16,049.85
Buy
65.80%
Upside
Reiterated
10/26/26
United Therapeutics price target raised to $850 from $700 at Cantor FitzgeraldUnited Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald
RBC Capital Analyst forecast on MX:UTHR
Lisa Walter
RBC Capital
RBC Capital
$13,368.58→$13,160.88
Buy
35.96%
Upside
Reiterated
10/22/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), Elevance Health (NYSE: ELV) and Abbott Laboratories (NYSE: ABT)
Raymond James Analyst forecast on MX:UTHR
Tiago Fauth
Raymond James
Raymond James
$12,934.29→$13,538.52
Buy
39.86%
Upside
Reiterated
10/20/26
United Therapeutics price target raised to $717 from $685 at Raymond JamesUnited Therapeutics price target raised to $717 from $685 at Raymond James
Leerink Partners Analyst forecast on MX:UTHR
Roanna Ruiz
Leerink Partners
Leerink Partners
$12,934.29→$13,689.58
Buy
41.42%
Upside
Assigned
10/20/26
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), United Therapeutics (UTHR)
Wells Fargo Analyst forecast on MX:UTHR
Benjamin Burnett
Wells Fargo
Wells Fargo
$13,217.52
Buy
36.54%
Upside
Reiterated
10/16/26
Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN), United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)
Goldman Sachs Analyst forecast on MX:UTHR
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$6,061.18→$6,948.64
Sell
-28.22%
Downside
Reiterated
10/15/26
United Therapeutics price target raised to $368 from $321 at Goldman SachsUnited Therapeutics price target raised to $368 from $321 at Goldman Sachs
UBS Analyst forecast on MX:UTHR
Ashwani Verma
UBS
UBS
$13,689.58
Buy
41.42%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), United Therapeutics (NASDAQ: UTHR) and Johnson & Johnson (NYSE: JNJ)
Bank of America Securities Analyst forecast on MX:UTHR
Jason Gerberry
Bank of America Securities
Bank of America Securities
$10,555.14
Hold
9.04%
Upside
Reiterated
10/09/26
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)
Morgan Stanley Analyst forecast on MX:UTHR
Terence Flynn
Morgan Stanley
Morgan Stanley
$10,687.31
Hold
10.41%
Upside
Reiterated
10/07/26
Morgan Stanley Releases a Hold Rating on United Therapeutics (UTHR)
BTIG Analyst forecast on MX:UTHR
Julian Harrison
BTIG
BTIG
$13,746.22
Buy
42.01%
Upside
Upgraded
10/01/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)
Jefferies Analyst forecast on MX:UTHR
Roger Song
Jefferies
Jefferies
$13,293.05
Buy
37.32%
Upside
Reiterated
10/01/26
Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Kazia Therapeutics (NASDAQ: KZIA) and FocalTherics (NASDAQ: FOCL)
TD Cowen Analyst forecast on MX:UTHR
Joseph Thome
TD Cowen
TD Cowen
$12,745.47
Buy
31.67%
Upside
Reiterated
09/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Medtronic (NYSE: MDT)
H.C. Wainwright Analyst forecast on MX:UTHR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$12,462.24
Buy
28.74%
Upside
Reiterated
08/06/26
Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds; $660 Price Target Maintained
Argus Research Analyst forecast on MX:UTHR
Jasper Hellweg
Argus Research
Argus Research
$10,574.02
Buy
9.24%
Upside
Assigned
03/03/26
United Therapeutics price target raised to $560 from $500 at ArgusUnited Therapeutics price target raised to $560 from $500 at Argus
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering United Therapeutics

3 Months
Roanna RuizLeerink Partners
Success Rate
16/19 ratings generated profit
84%
Average Return
+14.50%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +14.50% per trade.
1 Year
Roger SongJefferies
Success Rate
16/16 ratings generated profit
100%
Average Return
+30.88%
Copying Roger Song's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.88% per trade.
2 Years
Roanna RuizLeerink Partners
Success Rate
19/19 ratings generated profit
100%
Average Return
+74.67%
Copying Roanna Ruiz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +74.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UTHR Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
15
16
14
16
25
Hold
5
4
3
2
3
Sell
0
0
0
1
2
Strong Sell
0
0
0
0
0
total
20
20
17
19
30
In the current month, UTHR has received 25 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. UTHR average Analyst price target in the past 3 months is 12,636.22.
Each month's total comprises the sum of three months' worth of ratings.

UTHR Financial Forecast

UTHR Earnings Forecast

Next quarter’s earnings estimate for UTHR is $112.85 with a range of $82.66 to $136.41. The previous quarter’s EPS was $136.58. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s earnings estimate for UTHR is $112.85 with a range of $82.66 to $136.41. The previous quarter’s EPS was $136.58. UTHR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Sales Forecast

Next quarter’s sales forecast for UTHR is $14.68B with a range of $14.11B to $15.03B. The previous quarter’s sales results were $14.72B. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.
Next quarter’s sales forecast for UTHR is $14.68B with a range of $14.11B to $15.03B. The previous quarter’s sales results were $14.72B. UTHR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UTHR has Performed in-line its overall industry.

UTHR Stock Forecast FAQ

What is MX:UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is 12,636.22.
    What is MX:UTHR’s upside potential, based on the analysts’ average price target?
    United Therapeutics has 30.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is United Therapeutics a Buy, Sell or Hold?
          United Therapeutics has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 2 hold ratings and 1 sell ratings.
            What is United Therapeutics’s share price target?
            The average share price target for United Therapeutics is 12,636.22. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $16,049.85 ,and the lowest forecast is $6,948.64. The average share price target represents 30.54% Increase from the current price of $9,680.
              What do analysts say about United Therapeutics?
              United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of United Therapeutics?
                To buy shares of MX:UTHR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.